Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Panion Animal Health AB (Publ):First trading day for series 2019 warrants

Panion Animal Health AB today announced that the first trading day of warrants of series 2019 will be July 12, 2018. One (1) warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 1.31 per share. Subscription of shares under the warrants shall be in accordance with the terms of the warrants during the period from September 1, 2019 through September 30, 2019. Shares and share capitalThe preferential share issue of units has been partly registered at the Swedish Companies Registration Office and the total number of shares amounts to

LUNDIN GOLD CLOSES US$350 MILLION SENIOR DEBT FACILITY AND ANNOUNCES OFFTAKE AGREEMENT

VANCOUVER, CANADA, July 9, 2018 /CNW/ - Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) is pleased to announce that it has closed its previously announced senior secured project finance debt facility of $350 million (the “Facility”) with a syndicate of seven senior lenders to fund the development and construction of the Fruta del Norte gold project in Ecuador (“Fruta del Norte” or the “Project”). The Company has also executed a gold concentrate offtake agreement (the “Offtake”). All amounts in this release are in U.S. dollars unless otherwise indicated.

New Distributor Pedab Grows Clavister Channel Business in Northern Europe

One of the Nordics largest distributors adds Clavister to their vendor portfolio to enable secure business continuity to organizations throughout Scandinavia, Baltics and France. Distributing Clavister and using the technology will drive revenue growth and deepen market share.Örnsköldsvik, Sweden. 2018-07-09. Clavister, a leader in high-performance cybersecurity security solutions, today welcomes its newest distributor, Nordics based Pedab, who will begin offering Clavister to their extensive reselling network and as integrated technology in the Pedab Managed Security Services. Pedab is

Quarterly report Q2, 2018

Visma had another strong quarter with excellent top-line revenue and continued profit growth. Total revenue growth was 26.1% while EBITDA grew strongly as well by 23.5% over Q2 2017 to reach NOK 577 million. Download Q2 report  Revenues in each of Visma's four largest divisions (representing over 98% of EBITDA) grew well in excess of 20% year-on-year. The SMB Division grew revenues by 21%, Enterprise grew by an impressive 42%, Custom Solutions achieved 39% growth, and Commerce Solutions grew 25%

Presentation of Intrum’s results for January-June 2018

Intrum announces its’ interim results for January-June 2018 on 24 July 2018 at 7:00 a.m. CET. The report will be presented in a live webcast at 9:00 a.m. CET the same dayMikael Ericson, President & CEO and Thomas Moss, acting CFO, will present the results and answer questions. The conference will be held in English.To listen in to the conference live, please dial: +44 20 3008 9817 (UK)+46 8 5063 9549 (SE)+1 855 831 5947 (US) Link to live video cast  Link to video cast is also available on www.intrum.com. Participants are advised

Intervacc signs an agreement for future filling and release of Strangvac.

Strangvac is Intervacc's vaccine against strangles, which is a very severe and contagious infection in the horse. Intervacc has previously signed an agreement with 3P Biopharmaceuticals in Pamplona, Spain for large-scale commercial production of the components in Strangvac. The now signed agreement with Praxis Pharmaceuticals in Spain means that they will provide final formulation, filling of vials and packaging and final release of finished product. "With this agreement, we have been assured that the entire manufacturing chain is in place for commercial production of Strangvac. We look

HUNTER GROUP ASA: RESULT OF THE SUBSEQUENT OFFERING

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT.Oslo, July 9, 2018 Reference is made to the previous announcements by Hunter Group ASA (the “Company” or “Hunter”) relating to the subsequent offering of up to 16,250,000 new shares (the “Offer Shares”) for gross proceeds of up to NOK 52,000,000 (the “

Tecnotree announces rapid service creation initiative with a key operator in Iran

Tecnotree CorporationStock Exchange Release9 July 2018 at 13.30 EESTTecnotree announces rapid service creation initiative with a key operator in Iran Tecnotree has been selected by a key operator in Iran to accelerate time to market and agile responses to the market needs in their service creation and revenue generation capabilities by establishing a team of experts in collaboration with Tecnotree. The deal is significant to Tecnotree, as it is valued at USD 1.9 million and strengthens the well-established relationship with the company’s key customer in Iran. The customer has been

Camanio Care signs a new distributor for Bestic in Hong Kong

Camanio Care has signed a contract with Kerry Medical Ltd. for distribution of the assistive eating device Bestic. The contract is exclusive, which means that Kerry Medical becomes Camanio Cares exclusive distributor in Hong Kong.Hong Kong is potentially large market for Camanio Care’s eating assistive device Bestic. More than 16% of Hong Kong's population is over 65 years today, and it is estimated that doubling share to 2036. -       The agreement with Kerry Medical is strategic and completely in line with our ambitions in Hong Kong. We are very excited to become partner with such an

Ayima June 2018 Interim Sales Report

Ayima’s preliminary sales figure for the month of June 2018 is 14.2MSEK, a 37.5% increase from the same period in 2017 (10.4MSEK).Ayima continues to grow organically to plan and continues to invest in business development and marketing in order to have a strong sales pipeline to continue this trend. For further Information: CEO/VD Michael Jacobson +44-20 7148 5974 press(at)ayima.com www.ayima.com @AyimaGroupAbout Ayima Originally founded in 2007, Ayima is a digital marketing agency with around 145 employees across its offices in London, Stockholm, New York, San Francisco and

Chief Medical Officer appointed for clinical trials of world’s first therapy targeting both PMDD and menstrual migraine

Stockholm – June 29, 2018. A small Swedish pharmaceutical company has taken another step towards being the first company in the world to launch a targeted treatment for PMDD—the most debilitating form of PMS. Dr Märta Segerdahl has been appointed Chief Medical Officer, with over 20 years’ experience in pain medicine, including menstrual migraine.“There are very few drugs out there for the worst type of PMS,” says new Asarina Pharma CMO Märta Segerdahl. “And the ones we have are only moderately effective for some patients. I’ve been in this field for years, very few companies have come as

Multiconsult to deliver consultancy services in a significant contract for E6 between Ranheim and Værnes

Nye Veier has chosen Acciona Construccion S.A, Leonard Nilsen & Sønner, Acciona Mantenimiento de infrastructuras S.A. and Multiconsult for the EPC contract of approximately NOK 4 billion, developing and constructing the E6 between Ranheim and Værnes. The project is loacated in the municipalities Trondheim, Malvik and Stjørdal in Norway, and Multiconsult is to deliver all engineering services. The contract value for Multiconsult is significant, but still under negotiation.The contract is now in the clarification phase and will be signed in the end of September 2018. After approximately one

Transas to promote fleet efficiency for Wilson Ship Management

Wärtsilä Corporation, Press release, 9 July 2018 at 12.00 noon EESTTransas, a Wärtsilä company, has signed a landmark contract to supply a Fleet Operations Solution (FOS) to Wilson ASA, the Norway-based fleet operator. The FOS creates an infrastructure that includes onboard navigational and communication components to provide enhanced connectivity for business communications and crew services, and access to fleet data from shore-based locations for complete situational awareness. The order was booked in Q1, 2018.This will be one of the first applications of the Thesis concept within

Invitation to presentation of Bravida’s report for the second quarter 2018 on the 20th of July

Bravida’s report for the second quarter 2018 will be published 07:30 CET on the 20th of July.The report will be presented at 09:30 CET by CEO and Group President Mattias Johansson and CFO Nils-Johan Andersson. The presentation will be held in English and can be followed on the web or over the phone. There will be room for questions. Link to the webcast:https://tv.streamfabriken.com/bravida-q2-2018 Telephone numbers for telephone conference:SE: +46 8 5664 27 01UK: +44 20 3008 9810US: +1 85 5831 5945 The report and the presentation will be available on www.bravida.se/en/

Redwood Pharma has submitted an application for the start of clinical trial

Redwood Pharma has submitted its first national clinical trial application for the start of the RP101 trial. This application represents a significant milestone in the development of the Company’s novel treatment for chronic dry eye disease (DED) in postmenopausal women.“It is with satisfaction that we can announce that our first clinical trial application has been submitted to a national authority and ethical committee. The start of the clinical trial is planned for Q3 assuming required approvals have been granted. After completion of the toxicology studies at the end of 2017 and a

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release July 9, 2018, at 11:15 a.m. Nokian Tyres has received an announcement from Janus Henderson Group plc on July 2, 2018, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement Janus Henderson Group plc’s indirect holding in Nokian Tyres shares reached level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on June 29, 2018. The indirect shareholding was 6,879,364 shares, representing 5.00% of Nokian Tyres’ 137,484,660 shares and voting rights. Total

Invitation: Press and analyst conference

Holmen’s interim report for January–June 2018 will be published at lunchtime on Wednesday 15 August. In view of this, you are invited to watch the online broadcast of our press and analyst conference on the same day at 13.30.Time: 15 August at 13.30 CESTOnline broadcast: www.holmen.com/reports  Holmen President and CEO Henrik Sjölund will present and comment on the report. The presentation will be held in English. Note that this quarterly report will only be broadcast online. You may also participate in the conference by telephone, by calling: +46856642691 (within Sweden)

Ericsson expands the Connect to Learn initiative in India

· Ericsson’s mobile broadband solutions provide internet connectivity at 34 education centers run by Smile Foundation in five regions across India · The centers offer the Smile Twin E-learning Programme, an education program that helps unprivileged youth acquire the skills required to get jobs in the retail and service sectors · Ericsson has helped digitalize the program by developing web-based training modules, which has improved student attendance and retentionEricsson (NASDAQ: ERIC) has expanded the Connect to Learn initiative in India. The company’s mobile broadband solutions now

PHI´s new software available for customer delivery

The newly developed software HoloMonitor® App Suite has now successfully undergone the final field testing at selected HoloMonitor users around the world. Overall, the intuitive user interface, simple work flow, and the few steps to results are much appreciated. The very positive feed­back means that HoloMonitor® App Suite 1.0 is now, earlier than planned, available for sales. App Suite complements the existing Hstudio software, to allow basic cell analysis with a higher level of automation, and less manual work than before. In this first version of App Suite three common

Adelis acquires Didriksons

Didriksons has grown significantly in recent years and strengthened its position as one of the leading brands for rain- and functional wear in Scandinavia. To support the continued growth journey of the company, Adelis Equity Partners is acquiring a majority stake in Didriksons from a fund managed by Herkules Capital. Management will continue in their present roles and as significant owners in the company.Didriksons was founded in 1913 as a manufacturer of workwear for fishermen. Today, the company is a leader in Scandinavia within rain- and functional wear, and produces functional, durable

SenzaGen's final validation report for the animal-free allergy test GARDpotency™ has been submitted to the regulatory authorities

Lund, July 9, 2018. SenzaGen (Nasdaq First North: SENZA) announces today that the company has submitted the official validation report for GARDpotency™ to the relevant regulatory authorities as a complement to the validation of GARDskin™. GARDpotency™ is the first animal-free allergy test on the market that can be used to evaluate chemicals according to the EU's CLP classification. Other initiatives to measure potency today, including animal tests, only reach an accuracy of 55%-69%. Therefore, we at SenzaGen are extremely happy to be able to present the final results of the report showing

Publication of scientific article regarding the clinical trial with ProTrans

The stem cell company NextCell Pharma AB ("NXTCL") today announced, that a scientific article describing the ongoing clinical trial with ProTrans has been published in Clinical Trials in Degenerative Diseases (CTDD), a peer reviewed journal encompassing clinical trials, research, therapeutics and education within the field of degenerative diseases. The scientific article was written by Per-Ola Carlsson, principal investigator of the ongoing clinical study with ProTrans and Mathias Svahn, CEO of NXTCLThe title of the article is: “Wharton’s jelly derived allogeneic mesenchymal stromal cells

SOTKAMO SILVER: THE CONSTRUCTION OF THE DAMS, SETTLING PONDS AND THE OPEN PIT OF THE SILVER MINE PROJECT BEGINS

Sotkamo Silver have signed a contract with E. Hartikainen Oy concerning the stripping and earthmoving works and the construction of the dams and ponds. Kaitos Oy will install the membrane structures that is needed for the pond construction. The work begins at Monday July 9th. E. Hartikainen Oy is one of Finland’s leading and largest contractor company and reliable long-term partner for Sotkamo Silver with the highest possible credit rating. E. Hartikainen Oy has also participated as the contractor for the construction of roads in the mining area. Kaitos Oy is a leading geo synthetic

There are no items matching the current filter
There are no more items matching the current filter
Back to top